Sinvisk 6 ml syringe

• temporary replenishment or replacement of synovial fluid;
• treatment of patients suffering from osteoarthritis of the knee joint (gonarthrosis) at any stage of the disease;
• treatment of patients suffering from osteoarthritis of the knee joint (gonarthrosis) at any stage of the disease
• Effective recovery of patients constantly loading their joints and leading active lifestyle (athletes, workers engaged in heavy physical labor);
• exclusively intra-articular administration for pain relief in osteoarthritis of the knee.

.

Active ingredient

Composition

1 ml contains:

Active substances:

Hylan 8.0 mg;

Sodium chloride 8.5 mg;

Sodium hydrophosphate 0.16 mg;

sodium dihydrophosphate hydrate 0.04 mg;

water for injection.

How to take, the dosage

The Sinvisk injections must be performed exclusively in facilities officially certified for intra-articular injections, by licensed and certified physicians of the relevant profile and strictly in accordance with these instructions.

The recommended course of treatment with Sinvisk includes three injections into the cavity of the knee joint with an interval of 1 week. To achieve maximum effect, all three injections should be performed. The maximum recommended dose is six injections over six months with at least four weeks between courses.

The duration of effect in patients responding to treatment is usually at least twenty-six weeks, but more often than not, the time frame is longer. Treatment with Synvisc has an effect only on the affected joint where the drug is injected; there is no systemic effect with Synvisc.

Interaction

Don’t use disinfectants containing quaternary ammonium salts when treating the skin prior to injection.

Special Instructions

Sinvisk should not be injected if there is significant intra-articular effusion.

As with any invasive joint procedure, it is recommended that the patient be gentle and avoid excessive stress on the joint for several days following the Synvisc injection.

Sinvisk contains a small amount of chicken protein, so caution should be exercised when treating patients with related hypersensitivity.

The efficacy of a course of treatment containing fewer than three injections has not been established.

The efficacy and safety of Synvisc when used on joints other than the knee and for indications other than osteoarthritis have not been established.

Sinvisk has not been used to treat pregnant women or children under 18 years of age.

Anesthetics or other pharmacological agents should not be injected into the affected joint cavity during treatment with Synvisk.

Contraindications

Side effects

There may be transient pain, swelling in the injection area and/or the appearance of intra-articular exudation following a Synvisc injection. In some cases, the exudation may be significant and cause a more prolonged pain syndrome.

In these cases, it is necessary to perform a puncture of the joint and remove the exudate with subsequent microscopy to rule out infection and microcrystalline arthropathy (gout).

Usually these reactions disappear within a few days and do not affect the effectiveness of treatment.

In clinical trials of the drug, no cases of infection have been reported after Synvisc injections, and only a few cases have been reported in clinical use.